Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Investigator Initiated Study on Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy

NCT03770052 is registered in ClinicalTrials.gov with Pusan National University Hospital as lead sponsor.

NCT NCT03770052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03770052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Investigator Initiated Study on Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy
Lead sponsor
Pusan National University Hospital
Phase
Phase 4
Overall status
Completed
Start date
October 24, 2018
Completion date
September 13, 2021
Enrollment
159 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inadequate glucose control, type 2 diabetes mellitus